Advanced Ocular Systems Gains IP For Anti-VEGFs

Following up the merger with Australia-based Regenera Ltd. in a $31 million deal, Advanced Ocular Systems Ltd. broadened its intellectual property base by acquiring patent applications that, if granted, could cover the ocular use of anti-VEGF agents such as Genentech Inc.s Avastin. (BioWorld Today)